CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico. (February 2014)

• Record Type: Journal Article
• Authors: Lazalde-Ramos, Blanca Patricia; Martínez-Fierro, Margarita de la Luz; Galaviz-Hernández, Carlos; Garza-Veloz, Idalia; Naranjo, María Eugenia G; Sosa-Macías, Martha; LLerena, Adrián
• Is Part Of: Pharmacogenomics. Volume 15:Number 3(2014)
• Page Start: 339
• Page End: 348
• Publication Date: 2014-02
• Subjects: allele frequency -- CYP2D6 polymorphism -- Mexican indigenous -- pharmacogenetics -- predicted phenotype; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.13.203
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficiency; therefore, we determined the CYP2D6 allele distribution in eight Amerindian groups from northwestern Mexico and compared them with the frequencies in Mexican Mestizos.Materials & methods: A total of 508 Amerindians were studied. Genotyping of CYP2D6*5 and multiplication alleles was performed by long-range PCR, while CYP2D6*2, *3, *4, *6, *10, *17, *29, *35, *41 and copy number were evaluated by real-time PCR.Results: The most frequent alleles were CYP2D6*2 (0.05–0.28), CYP2D6*4 (0.003–0.21) and multiplications (0.043–0.107). CYP2D6*5, *6, * 10 and *41 were not observed in the majority of Amerindians, and CYP2D6*3, *17, *35 and *29 were not detected. The poor metabolizer genotype ( *4/*5 ) was lower (0.2%) in Amerindians than in Mestizos (5%); conversely, the ultrarapid metabolizer genotype was higher (12.6%) in indigenous groups than in Mestizos (7%).Conclusion: Our data show a lower frequency of CYP2D6 inactive alleles and a higher frequency of duplication/multiplication of CYP2D6 active alleles in indigenous populations that in Mestizos. Original submitted 14 August 2013; Revision submitted 7 October 2013